Comment

Most consider the debate over the naming convention for biologics arcane and esoteric, and few will read this, but it is very important for the sector. PharmaDispatch has tried to capture the history and complexity of a debate that remains unresolved.

An organisation that regularly takes an anti-industry editorial line, to the extent it rarely runs positive industry stories in its publications - unless they are paid for - has zero right to sit in judgement of this great Australian industry and its employees.

A significant day for Medicines Australia with PharmAus17 but maybe not for the reasons most people would expect.

The situation is a charade, with enormous and long-term strategic implications for industry, as the Trump administration talks tough on trade while taking actions that undermine the outcomes it claims to support.

Reading between the lines, government's response to the Productivity Commission's review of intellectual property arrangements is an absolute 'slam dunk' for the research-based pharmaceutical industry.

Maybe the best way to judge someone's legacy is whether they leave an organisation in better shape than when they started.

You just wonder whether a company effectively using Professor Andrew Wilson's supportive words against him is such a good idea.

The problem with independent reviews can be their independence - they are independent to come up with really bad ideas.

Anyone who has attended one of these events, or even bothered to gather accurate information about them, will know most healthcare professionals attend in spite of the food, not because of it

The proposed change to the payment and budgeting of rebates is clearly a policy change. The association has not been consulted.

The supply and pricing of PBS medicines to hospitals is one of the sector's worst-kept secrets - nobody should really be surprised the system is experiencing extensive shortages given current procurement practices.

The Turnbull government is promoting an innovation agenda, through policy vehicles like the Medical Research Future Fund, while slowly chipping away at other important components of the eco-system.